RVMD at a glance
Revolution Medicines Inc (RVMD, SEC CIK 1628171) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 1, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Revolution Medicines Inc (RVMD) reported revenue of $0 and a net loss of $1.1 billion. Diluted EPS was -$5.95.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Revolution Medicines Inc (RVMD) shares worth $13.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sandler Alan B. on September 29, 2026 of 1,199 shares at $203.91 per share.
- In the last 90 days, RVMD insiders reported 0 open-market purchases ($0) and 79 open-market sales ($78.0M) on Form 4, a net sale of $78.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 79 sells
- Net −$78.0M
- 13F holders
- 35 funds
- $13.1B · +1 vs prior quarter
- Latest 10-Q
- Aug 5, 2026
- Quarterly report
SignalX for RVMD
Don't miss the next RVMD filing
- Alerts as it files. A push when RVMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RVMD, by share count.
- Ask anything. An AI agent that reads every RVMD filing and answers with sources.
RVMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sandler Alan B. | Sell | Sep 29, 2026 | 1,199 | $203.91 |
| Sandler Alan B. | Sell | Sep 29, 2026 | 1,000 | $202.81 |
| Sandler Alan B. | Sell | Sep 29, 2026 | 301 | $204.72 |
| Sandler Alan B. | M | Sep 29, 2026 | 6,000 | - |
| Sandler Alan B. | M | Sep 29, 2026 | 6,000 | $58.84 |
| Sandler Alan B. | Sell | Sep 29, 2026 | 1,609 | $201.72 |
| Sandler Alan B. | Sell | Sep 29, 2026 | 2,200 | $200.82 |
| Mancini Anthony | Sell | Sep 25, 2026 | 3,121 | $200.54 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $11.6M | $0 | $0 |
| Operating Income | - | -$689.5M | -$1.2B |
| Net Income | -$436.4M | -$600.1M | -$1.1B |
| Net Margin | -3768.3% | - | - |
| Balance Sheet | |||
| Total Assets | - | $2.6B | $2.4B |
| Equity | $1.8B | $2.3B | $1.6B |
| ROE | -23.9% | -26.5% | -69.3% |
| Per Share | |||
| EPS | - | $-3.58 | $-5.95 |
| Cash Flow | |||
| Operating CF | - | -$557.4M | -$897.7M |
| CapEx | $7.7M | $10.3M | $16.0M |
Source: XBRL data in Revolution Medicines Inc (RVMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RVMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $13.12B |
| Q1 2026 | 34 | $5.80B |
| Q4 2025 | 29 | $4.73B |
| Q3 2025 | 31 | $2.95B |
| Q2 2025 | 31 | $2.28B |
| Q1 2025 | 25 | $1.66B |
| Q4 2024 | 21 | $1.70B |
| Q3 2024 | 19 | $639.4M |
- FMR LLC (Fidelity)+3.74M (+44%)
- JPMorgan Chase & Co+3.00M (+994%)
- BlackRock+2.48M (+22%)
- AQR Capital Management+1.18M (+1009%)
- Vanguard Portfolio Management LLC+792.2K (+11%)
- D.E. Shaw & Co−1.01M (-99%)
- T. Rowe Price Group−841.9K (-26%)
- Two Sigma Investments−821.1K (-53%)
- Ameriprise Financial−540.1K (-34%)
- Alphabet Inc−345.9K (-11%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 225 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RVMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
RVMD SEC filings: frequently asked questions
Are RVMD insiders buying or selling?
In the last 90 days, Revolution Medicines Inc (RVMD) officers, directors and 10% owners reported no open-market purchases and 79 open-market sales worth $78.0 million by 9 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RVMD stock?
As of June 30, 2026, the largest Revolution Medicines Inc (RVMD) holders among the 13F filers tracked by SignalX were BlackRock ($2.6 billion), FMR LLC (Fidelity) ($2.3 billion), Vanguard Capital Management LLC ($1.7 billion), Vanguard Portfolio Management LLC ($1.6 billion), State Street Corp ($917.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RVMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Revolution Medicines Inc (RVMD) reported revenue of $0 and a net loss of $1.1 billion. Diluted EPS was -$5.95. The figures come from the XBRL data in the 10-K.
What are the latest RVMD SEC filings?
Revolution Medicines Inc (RVMD) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 1, 2026 and a Form 4 insider filing on October 1, 2026.
What is RVMD's SEC CIK number?
Revolution Medicines Inc (RVMD)'s SEC Central Index Key (CIK) is 1628171. EDGAR lists every RVMD filing under that number.
Ask anything about RVMD
The research agent reads RVMD's filings, financials, insider trades and 13F holders, then answers with sources.